Mechanistic and predictive profiling of 5-fluorouracil resistance in human cancer cells

Cancer Research

Volumn 64, Issue 22, 2004, Pages 8167-8176

  Wang, Weiguang ^a   Cassidy, James ^a   O'Brien, Vincent ^a   Ryan, Kevin M ^a   Collie Duguid, Elaina ^b  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLICE INHIBITORY PROTEIN; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OROTATE PHOSPHORIBOSYLTRANSFERASE; PYRIMIDINE NUCLEOSIDE PHOSPHORYLASE; THYMIDINE KINASE; URIDINE PHOSPHATE;

ARTICLE; BINDING AFFINITY; BREAST ADENOCARCINOMA; CANCER; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEATH; CONTROLLED STUDY; DNA BINDING; DNA FINGERPRINTING; DNA MICROARRAY; DNA REPAIR; DNA REPLICATION; DNA TRANSFECTION; DOWN REGULATION; GENE EXPRESSION; GENETIC RESISTANCE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; UNINDEXED SEQUENCE;

BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FLUOROURACIL; G1 PHASE; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE;

EID: 8544224306     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0970     Document Type: Article

References (37)

1. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
2. Sobrero A, Kerr D, Glimelius B, et al. New directions in the treatment of colorectal cancer: a look to the future. Eur J Cancer 2000;36:559-66.
3. Adjei AA. A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. Br J Clin Pharmacol 1999;48:265-77.
4. Wang W, Marsh S, Cassidy J, McLeod HL. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res 2001;61:5505-10.
5. Copur S, Aiba K, Drake JC, Allegra CJ, Chu E. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 1995;49:1419-26.
6. Debouck C, Goodfellow PN. DNA microarrays in drug discovery and development. Nat Genet 1999;21:48-50.
7. Plumb JA, Milroy R, Kaye SB. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res 1989;49:4435-40.
8. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science (Wash D C) 1996;274:784-7.
9. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999;5:412-7.
10. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. [Review]. Oncogene 1999;18:6910-24.
11. Wang W, Cassidy J. Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor resistant tumour cells. Br J Cancer 2003;88:624-9.
12. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature (Lond) 1997;388:190-5.
13. Blagosklonny MV, Pardee AB. The restriction point of the cell cycle. Cell Cycle 2002;1:103-10.
14. Maxwell PJ, Longley DB, Latif T, et al. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res 2003;63:4602-6.
15. Cusack JC Jr, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001;61:3535-40.
16. Wang W, McLeod HL, Cassidy J. Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 2003;104:504-11.
17. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science (Wash D C) 1998;281:1680-3.
18. Wu MX, Ao Z, Prasad KV, Wu R, Schlossman SF. IEX-1L, an apoptosis inhibitor involved in NF-kappaB-mediated cell survival. Science (Wash D C) 1998;281:998-1001.
19. Wang CY, Guttridge DC, Mayo MW, Baldwin AS Jr. NF-kappaB induces expression of the Bcl-2 homologue Al/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999;19:5923-9.
20. Krueger A, Baumann S, Krammer PH, Kirchhoff S. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 2001;21:8247-54.
21. Eichhorst ST, Muerkoster S, Weigand MA, Krammer PH. The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system. Cancer Res 2001;61:243-8.
22. Houghton JA, Harwood FG, Tillman DM. Thymineless death in colon carcinoma cells is mediated via fas signaling. Proc Natl Acad Sci USA 1997;94:8144-9.
23. Iwase M, Watanabe H, Kondo G, Ohashi M, Nagumo M. Enhanced susceptibility of oral squamous cell carcinoma cell lines to FAS-mediated apoptosis by cisplatin and 5-fluorouracil. Int J Cancer 2003;106:619-25.
24. Kreuz S, Siegmund D, Scheurich P, Wajant H. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 2001;21:3964-73.
25. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 2001;21:5299-305.
26. Agarwal RP, Han T, Fernandez M. Reduced cellular transport and activation of fluoropyrimidine nucleosides and resistance in human lymphocytic cell lines selected for arabinosylcytosine resistance. Biochem Pharmacol 2001;61:39-47.
27. Chung YM, Park S, Park JK, et al. Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett 2000;159:95-101.
28. Dolnick BJ, Black AR, Winkler PM, Schindler K, Hsueh CT. rTS gene expression is associated with altered cell sensitivity to thymidylate synthase inhibitors. Adv Enzyme Regul 1996;36:165-80.
29. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689-95.
30. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-31.
31. Bartek J, Lukas J. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett 2001;490:117-22.
32. Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 2000;14:2393-409.
33. Sears RC, Nevins JR. Signaling networks that link cell proliferation and cell fate. J Biol Chem 2002;277:11617-20.
34. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-7.
35. Pohl G, Rudas M, Taucher S, et al. Expression of cell cycle regulatory proteins in breast carcinomas before and after preoperative chemotherapy. Breast Cancer Res Treat 2003;78:97-103.
36. Takeuchi H, Ozawa S, Ando N, et al. Cell-cycle regulators and the Ki-67 labeling index can predict the response to chemoradiotherapy and the survival of patients with locally advanced squamous cell carcinoma of the esophagus. Ann Surg Oncol 2003;10:792-800.
37. Mirjolet JF, Didelot C, Barberi-Heyob M, Merlin JL. G(1)/S but not G(0)/G(1)cell fraction is related to 5-fluorouracil cytotoxicity. Cytometry 2002;48:6-13.